[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Clinique Pasteur\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":95},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100490225","study-on-treatment-of-varicose-veins-by-endovenous-laser-1940-nm-vs-1470-nm-100490225",false,"NCT05663359","Study on Treatment of Varicose Veins by Endovenous Laser (1940 nm vs 1470 nm)","Randomized Comparative Study With Two Wavelengths 1470 nm and 1940 nm for the Treatment of Varicose Veins of the Lower Limbs by Endovenous Laser.","NEWWAVE","Inclusion Criteria:\n\n* Primary insufficiency of the great saphenous vein (GSV) and\u002For small saphenous vein (SSV)\n* Patient candidate for endothermic treatment of the lower limbs\n* CEAP: C2 - C6\n* Patient with a target vein diameter (GSV and\u002For SSV) \\>= 3 mm throughout the target vein segment\n* Patient affiliated or beneficiary of a social security scheme\n* Patient having signed the informed consent\n\nExclusion Criteria:\n\n* Patient with a current serious pathology and\u002For a life expectancy of less than 5 years\n* Patient who has had a deep or superficial vein thrombosis in the previous 6 months\n* Obliterating arteriopathy of the lower limb concerned, with an IPS \\\u003C 0.8 or \\> 1.3\n* Patient with post-thrombotic obstructive syndrome at the popliteal and\u002For femoral and\u002For iliac stage on the ipsilateral lower limb\n* Patient with primary or post-thrombotic axial deep venous reflux on the ipsilateral lower limb\n* Suspicion of non-post-thrombotic iliac compression on echo-doppler\n* Contraindication to the planned treatment technique\n* Patient whose geographical distance is not compatible with the follow-up of the study\n* Pregnant or breastfeeding women\n* Patient linguistically or psychologically unable to understand the information given, to give informed consent or to answer the study questionnaires.\n* Protected patients: Adults under guardianship, or other legal protection; Hospitalized without consent.","ALL","18 Years",{"count":20,"type":21},280,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to compare efficacy of two wavelength for EndoVenous Laser Ablation (EVLA) in treatment of varicose veins of the lower limbs.\n\nThe main questions it aims to answers are :\n\n1. Is the increase of wavelength form 1470 nm to 1940 nm affect the efficacy of varicose veins treatment ?\n2. Is the increase of wavelength reduce complication or pain ? Participants are patients with varicose veins of lower limbs and candidate for endovenous laser ablation.\n\nAfter laser ablation patients will be followed during 5 years for clinical evaluation, recording potential treatment complications and quality of life evaluation.\n\nResearchers will compare strategy 1(EVLA with an endovenous laser at 1940 nm) vs strategy 2 (EVLA with an endovenous laser at 1470 nm) in varicose veins treatment to see if efficacy of treatment is not reduce, and to see if complications of EVLA treatment can be reduced.",[27],"Varicose Veins",[29],"Endovenous laser ablation (EVLA)","RECRUITING","2026-03-05",{"date":33,"type":34},"2026-03-06","ACTUAL",{"date":36,"type":34},"2023-02-24",{"date":38,"type":21},"2032-02",{"name":40,"class":41},"Clinique Pasteur","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":42},"100349933","study-of-the-contribution-of-osteopathic-treatment-to-classic-medical-management-in-patients-with-chronic-low-back-pain-100349933","NCT03836248","Study of the Contribution of Osteopathic Treatment to Classic Medical Management in Patients With Chronic Low Back Pain","Inclusion Criteria:\n\n* Patient with chronic non-specific low back pain: degenerative lumbalgia and low back pain unrelated to anatomical lesions that have been evolving for more than 3 months.\n* Patient affiliated with a social security scheme or equivalent\n* Patient having signed the study informed consent form.\n\nExclusion Criteria:\n\n* Patient with specific low back pain: patient with one of the following pathologies: degenerative neurological pathology; infectious pathology; fracture vertebral lesion less than 1 year; vertebral osteosynthesis material or canal narrowing.\n* Patient following a treatment of the Morphinic or Neuroleptic type.\n* Pregnant, breastfeeding or parturient woman\n* Patient participating in another clinical study\n* Protected patient: Major under some form of guardianship ; Hospitalized without consent","64 Years",{"count":51,"type":21},199,[24],"The management of chronic low back pain is now part of a multi-disciplinary set of proposals with the aim of adapting for each patient orientations of both medicated and non-medicated care.\n\nVery classically, analgesic treatment of stage I or II is of use, reinforced by the occasional use of NSAIDs in the absence of contraindication. In this medical attempt of the control of the pain associates a physical care (supervised exercises, physiotherapy care), cognitive and behavioral therapy, multidisciplinary care.\n\nOsteopathic treatment is a specific manual diagnostic and therapeutic procedure.\n\nThis study aims to evaluate the relevance of providing osteopathic treatment in combination with classical medical treatment in the management of patients with chronic non-specific low back pain.",[55],"Chronic Low Back Pain",[57,58,59],"Osteopathic treatment","Sham osteopathic treatment","Low back pain",{"date":33,"type":34},{"date":62,"type":34},"2019-10-02",{"date":64,"type":21},"2028-09",{"name":40,"class":41},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":74,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":42},"100308589","stop-or-ongoing-oral-anticoagulation-in-patients-undergoing-pvp-soap-100308589","NCT03297281","Stop or Ongoing Oral Anticoagulation in Patients Undergoing Pvp (SOAP)","Multicenter Randomized Open-labelled Trial Which Aims to Show Non-inferiority of Adverse Events Risk During the Maintenance of Oral-anticoagulation in the Surgery of Benign Prostatic Hypertrophy by Laser Photovaporization","SOAP","Inclusion Criteria:\n\n* Prostate volume \\\u003C or = 30 gr\n* Micturition disorders resistant to medical treatment related to HBP and\u002For complications related to BPH (retention, lithiasis...)\n* Patient candidate for photovaporization of the prostate\n* Patient under treatment AVK (Anti Vitamin K) for more than 3 months with an objective of INR (International Normalized Ratio) between 2 and 3 or patient under DOACs (Direct Oral Anti-coagulants) for more than 3 months\n* Unprotected major\n* Patient affiliated to a social security scheme or equivalent\n* Patient is willing and able to comply with all study requirements and to sign a study-specific informed consent form.\n\nExclusion Criteria:\n\n* History of prostate cancer\n* Previous pelvic radiotherapy\n* History of stenosis of the urethra\n* Patient with one or more bladder polyps\n* Patient under antiplatelet agent other than aspirin\n* Allergy to heparin or history of heparin-induced thrombocytopenia\n* Patients under anticoagulant injectable therapy at baseline (heparin, LMWH (Low Molecular Weight Heparin), fondaparinux)\n* Any mechanical prosthetic heart valve\n* Stroke (ischemic or hemorrhagic), systemic embolism or transient ischemic attack within past 12 weeks\n* Venous thromboembolism (deep vein thrombosis and\u002For pulmonary embolism) within past 12 weeks\n* Major bleeding within past 6 weeks\n* Severe renal insufficiency (calculated creatinine clearance \\\u003C 30 mL \u002F min)\n* Thrombocytopenia (platelet count \\\u003C 100 x 10\\^9 \u002F L)\n* Life expectancy \\\u003C 1 month\n* Condition that impairs compliance with trial protocol (e.g. cognitive impairment, uncontrolled psychiatric condition, geographic inaccessibility)\n* Contra-indication to PVP surgery or contra-indication to general anesthesia\n* Protected patients : majors under some form of guardianship\n* Patient participating in another clinical study","MALE",{"count":76,"type":21},389,[24],"Benign prostatic hyperplasia (BPH) is a very common pathology of the aging man with an incidence that rises from 40% in men aged 50 to 60 years to 90% in men over 80 years. Studies such as the MTOPS (the Medical Therapy of Prostatic Symptoms) study show that more than half of the patients recruited had an aggravation of their disease over time either by an increase in symptoms or by the appearance of complications such as acute retention of urine.\n\nFor benign symptomatic prostate hypertrophy, apart from any complication, first-line treatment is now a medical treatment. For patients who respond poorly to medical treatment or who have complications related to benign prostatic hypertrophy, the treatment becomes surgical. The reference treatment is endoscopic prostate resection (TURP). It is mainly to improve the safety of hemostasis in patients older and older and at significant surgical risk that new \"minimally invasive\" surgical techniques have emerged. Thus, lasers have been developed and are currently used as an alternative to the TURP. Used in clinical practice since 2000, prostatic photosensitive vaporization (PVP) relies on the absorption of a 532nm (green) wavelength laser beam by the oxyhemoglobin contained in richly vascularized prostate tissue.\n\nGiven the aging of the population, more and more patients are being treated with oral anticoagulants (Anti Vitamin K (AVK) or direct oral anticoagulants (DOACs)). Today there are about 1.4 million people on oral anticoagulants, 40% of whom are over 80 years of age. The peri-operative management of the AVK is currently based on the recommendations published by the FHA (French Health Authority) in 2008. Concerning the perioperative management of DOACs, the perioperative haemostasis interest group (GIHP) made proposals updated in September 2015.\n\nNumerous studies published in the literature have concluded the feasibility of prostate removal surgery by PVP with greenlight laser without relay (or interruption) of AVK or DOACs because of the properties of hemostasis. But the levels of evidence for these studies remain low.\n\nNo study has focused on rigorously assessing the perioperative hemorrhagic risk associated with OAC therapy in patients eligible for PVP, and this is the originality of this study.\n\nThis study is a multicenter prospective randomized study whose objective is to show that the PVP performed in patients with OAC is not associated with an increase in perioperative hemorrhagic risk.",[80,81],"Benign Prostatic Hyperplasia","Anticoagulant Adverse Reaction",[83,84,85,86,87],"Photovaporization","Laser","Benign prostatic hyperplasia","Oral anticoagulation","Complication","2026-03-04",{"date":33,"type":34},{"date":91,"type":34},"2017-10-30",{"date":93,"type":21},"2028-05-31",{"name":40,"class":41},""]